Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema

NCT04292912 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04292912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04292912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
September 7, 2020
Completion date
April 11, 2022
Enrollment
16 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

macular edema